Please login to the form below

Not currently logged in
Email:
Password:

tetrabenazine

This page shows the latest tetrabenazine news and features for those working in and with pharma, biotech and healthcare.

FDA approves Teva's Huntington's disease drug at second attempt

FDA approves Teva's Huntington's disease drug at second attempt

The green light gives patients with HD in the US the first alternative to Lundbeck's already approved Xenazine (tetrabenazine) drug, which was launched onto the market in 2008. ... looking at symptom control in patients who switch to Teva's drug from

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    In a statement, Teva said that the metabolites under scrutiny by the FDA are not novel, and are also seen in patients who take tetrabenazine. ... It is estimated that because of tolerability issues only around 5% of eligible Huntington's disease patients

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but ... Tetrabenazine is approved as an orphan drug in the US to treat chorea

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of

  • Lundbeck still feeling effects from Cipralex patent loss Lundbeck still feeling effects from Cipralex patent loss

    Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....